In Reply We agree with Sperl-Hillen and colleagues that inappropriate use of aspirin for the primary prevention of atherosclerotic cardiovascular disease (ASCVD) is common in clinical practice. This underscores the important need for improving evidence–based decision making through tools that facilitate the personalized benefit to risk assessment. The Aspirin-Guide decision support tool (freely available as an app for mobile devices and also on the web at http://www.aspiringuide.com) is designed to help busy clinicians in shared decision–making discussions with their patients regarding aspirin use.1,2 This user-friendly decision support tool rapidly provides individualized bleeding and ASCVD risk score assessments, along with an evidence-based specific recommendation for the patient based on these dual risk assessments.
Mora S, Manson JE. Risk and Benefit Information and Use of Aspirin—Reply. JAMA Intern Med. 2017;177(2):291–292. doi:https://doi.org/10.1001/jamainternmed.2016.7991
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: